Anthracycline-based adjuvant chemotherapy is very effective in early breast cancer, but there are limited data on the use of epirubicin in patients with chronic renal failure undergoing hemodialytic treatment. We report the case of a patient with early breast cancer and chronic renal failure who was treated with adjuvant weekly epirubicin. Treatment was well tolerated. The patient is still alive and relapse free 58 months after surgery. If the patient will be disease free after 5 years, she will be reconsidered for renal transplantation. In conclusion, weekly epirubicin appears to be a safe adjuvant chemotherapy option for early breast cancer patients with chronic renal failure undergoing hemodialytic treatment.
Early Breast Cancer Trialists’ Collaborative Group:Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet, 365: 1687–1717, 2005.
2.
SobinL.H., WittekindC.: International Union Against Cancer.TNM classification of malignant tumours, 5th Edition, John'’ Wiley & Sons, New York, 1997.
3.
YoshidaH., GotoM., HondaA., NabeshimaT., KumazawaT., InagakiJ., YamanakaN., OtaK.: Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.Cancer Chemother Pharmacol, 33: 450–454, 1994.
4.
GundersenS., KvinnslandS., KleppO., KvaloyS., LundsE., HostH.: Weekly adriamycin versus VAC in advanced breast cancer.A randomized trial. Eur J Cancer Oncol, 22: 1431–1434, 1986.
5.
GundersenS., KvinnslandS., KleppO., LundsE., HostH.: Weekly adriamycin vs.4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norvegian Breast Cancer Group. Eur J Cancer, 26: 45–48, 1990.
6.
BlomqvistC., ElomaaI., RissanenP., HietanenP., NevasaariK., HelleL.: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.J Clin Oncol, 11: 467–473, 1993.
7.
ColozzaM., BisagniG., MosconiA.M., GoriS., BoniC., SabbatiniR., FrassoldatiA., PassalacquaR., Rosa BianA., RodinòC., RondiniE., AlgeriR., Di SarraS., De AngelisV., CocconiG., TonatoM.: Epirubicin vs CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.Eur J Cancer, 38: 2279–2288, 2002.
